Staphylococcus (e.g., Staphylococcus Aureus, Etc.) Patents (Class 424/243.1)
-
Publication number: 20140050732Abstract: The present invention relates a combination for use in the treatment and/or prevention of mastitis containing i) an agonistic anti-CD40 monoclonal antibody or a CD40 ligand or a vector coding for the anti-CD40 antibody or a vector coding for the CD40L; and ii) inactivated or attenuated bacteria selected from the group consisting of Staphylococcus, Streptococcus, Listeria or Escherichia.Type: ApplicationFiled: March 15, 2013Publication date: February 20, 2014Inventors: Fabrice Bureau, Hughes Wallemacq, Philippe Boutet, Pierre Lekeux, Laurence Fievez, Julien Pujol
-
Patent number: 8647640Abstract: The present invention provides a novel immunogenic composition, vaccine and methods for making and using the immunogenic composition and vaccine. The immunogenic composition is capable of providing an immune response and/or a protective immunity into subjects, preferably mammals, against microorganism-associated disease. The immunogenic composition includes one or more extracellular proteins isolated from a microorganism capable of providing an immune response and/or a protective immunity into subjects against microorganism-associated disease. The isolated extracellular proteins range in molecular weight from about 10,000 Da to about 220,000 Da. Suitable microorganisms may include members of the genus Salmonella, Listeria, Pseudomonas, Staphylococcus, and Vibrio. Kits are also encompassed for detection, diagnosis and prevention of microorganism-associated disease.Type: GrantFiled: June 23, 2010Date of Patent: February 11, 2014Inventor: Richard E. Cowart
-
Publication number: 20140037716Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.Type: ApplicationFiled: March 19, 2012Publication date: February 6, 2014Inventor: Alexandre Eduardo Nowill
-
Patent number: 8632783Abstract: Staphylococcus aureus Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunization are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens, including Hla polypeptides having deletions, insertions, and/or mutations, are identified for use in immunization. These polypeptides may optionally be used in combination with S. aureus saccharides.Type: GrantFiled: September 15, 2011Date of Patent: January 21, 2014Assignee: Novartis AGInventors: Fabio Bagnoli, Luigi Fiaschi
-
Patent number: 8623371Abstract: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-?-glutamic acid (such as ?DLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagonosed with the infection by the Staphylococcus organism which expresses ?PGA from the cap genes. Further, the expression of a ?PGA polypeptide by the organism can then be altered.Type: GrantFiled: July 20, 2012Date of Patent: January 7, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Michael Otto, Stanislava Kocianova
-
Publication number: 20130295137Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: ApplicationFiled: July 3, 2013Publication date: November 7, 2013Inventors: Jiri Pillich, John C. Balcarek
-
Publication number: 20130287813Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.Type: ApplicationFiled: July 1, 2013Publication date: October 31, 2013Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
-
Patent number: 8568735Abstract: The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using immunogenic compositions of the Staphylococcus aureus polypeptides and capsule polysaccharides.Type: GrantFiled: June 22, 2010Date of Patent: October 29, 2013Assignee: Wyeth LLCInventors: Annaliesa Anderson, Viliam Pavliak, Kathrin Ute Jansen, Ingrid Lea Scully, Steven Morris Baker, Jasdeep Singh Nanra, Ellen Murphy, Bruce Arthur Green, Mark Edward Ruppen, Yekaterina Timofeyeva
-
Patent number: 8568731Abstract: The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising the polypeptides; recombinant methods to manufacture the polypeptides; and therapeutic antibodies directed to the polypeptides.Type: GrantFiled: September 8, 2009Date of Patent: October 29, 2013Assignee: Biosynexus IncorporatedInventors: Simon Foster, Philip McDowell, Kirsty Brummell, Simon Clarke
-
Publication number: 20130280300Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.Type: ApplicationFiled: July 1, 2013Publication date: October 24, 2013Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
-
Publication number: 20130259896Abstract: The present invention is directed towards a lyophilized or reconstituted multi-antigen or multicomponent immunogenic composition comprising at least one antigen isolated from a staphylococcal bacterium, and methods of making the same.Type: ApplicationFiled: December 21, 2011Publication date: October 3, 2013Inventors: Lakshmi Khandke, Akihisa Nonoyama, Tamara Shafer Hodge, Sandeep Nema
-
Patent number: 8545853Abstract: It refers to a recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, comprising a deletion in the stem domain, wherein at least one heterologous sequence is inserted in a region selected from the group consisting of regions defined by amino acid position of 108 to 151, 1 to 5, 288 to 293, 43 to 48, 235 to 240, 92 to 97, 31 to 36,or 156 to 161 of SEQ ID NO: 1, with the proviso that, if the heterologous sequence contains five or more consecutive histidines the moiety of the heterologous sequence other than the moiety of five or more consecutive histidines has a minimum length of 11 amino acids; or a variant thereof comprising 1-50 amino acids added, substituted or deleted in SEQ ID NO. 1 and the activity to form oligomers and to bind to lipidic bilayers. It also provides a medicament and vaccine comprising said recombinant polypeptide.Type: GrantFiled: January 15, 2010Date of Patent: October 1, 2013Assignees: Universite de Liege, Centre d'Economie Rurale, Universite Libre de BruxellesInventors: Patrice Filee, Noureddine Rhazi, Moreno Galleni, Bernard Taminiau, Olivier Jolois, Alfred Collard, Alain Jacquet
-
Publication number: 20130236419Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve attenuated S. aureus strains having deletions in their genome, such as in the srtA and saeR regions.Type: ApplicationFiled: September 9, 2011Publication date: September 12, 2013Applicant: THE UNIVERSITY OF CHICAGOInventors: Olaf Schneewind, Hye-Young Kim, Dominique M. Missiakas, Hwan Keun Kim
-
Publication number: 20130230550Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant. In some embodiments, the methods and compositions involve SdrD, ClfA, and/or FnbpB polypeptides.Type: ApplicationFiled: September 9, 2011Publication date: September 5, 2013Applicant: The University of ChicagoInventors: Olaf Schneewind, Alice G. Cheng, Dominique M. Missiakas, Hwan Keun Kim, Hye-Young Kim
-
Patent number: 8518416Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: GrantFiled: October 24, 2011Date of Patent: August 27, 2013Assignee: Immunology Laboratories, Inc.Inventors: Jiri Pillich, John C. Balcarek
-
Publication number: 20130209501Abstract: The present invention relates to immunogenic compositions, comprising polypeptides isolated from Staphylococcus epidermidis. The invention also relates to polynucleotides encoding Staphylococcus epidermidis polypeptides and their use in immunogenic compositions. In addition, the invention relates to methods of inducing an immune response in mammals against Staphylococcus epidermidis and Staphylococcus aureus using immunogenic compositions of the Staphylococcus epidermidis polypeptides and polynucleotides. The invention also relates to methods for detecting Staphylococcus epidermidis in a biological sample.Type: ApplicationFiled: April 19, 2013Publication date: August 15, 2013Applicant: Wyeth LLCInventor: Wyeth LLC
-
Patent number: 8492519Abstract: The present invention relates to a modified polypeptide with a biological activity to lyse cell walls of bacteria, wherein the polypeptide has no caspase, clostripain, enterokinase, factor Xa, granzyme B, staphylococcus peptidase I (V8 Protease), plasmin, streptopain, bacillolysin and/or thrombin cleavage site. The invention further relates to nucleic acids with a sequence encoding a polypeptide according to the present invention.Type: GrantFiled: August 19, 2008Date of Patent: July 23, 2013Assignees: Hyglos Invest GmbH, bioMérieux S.A.Inventors: Holger Grallert, Michael Forchheim
-
Publication number: 20130183339Abstract: Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2? deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2? deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150,Type: ApplicationFiled: March 6, 2013Publication date: July 18, 2013Applicant: Intercell AGInventor: Intercell AG
-
Patent number: 8481053Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: GrantFiled: August 30, 2011Date of Patent: July 9, 2013Assignee: Immunology Laboratories, Inc.Inventors: Jiri Pillich, John C. Balcarek
-
Publication number: 20130156802Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.Type: ApplicationFiled: December 16, 2011Publication date: June 20, 2013Inventor: Juliette Tinker
-
Patent number: 8465750Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.Type: GrantFiled: November 9, 2011Date of Patent: June 18, 2013Assignee: Novartis AGInventors: Vega Masignani, Marirosa Mora, Maria Scarselli
-
Publication number: 20130142825Abstract: The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.Type: ApplicationFiled: May 26, 2011Publication date: June 6, 2013Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.Inventors: Josep Bassaganya-Riera, Amir Guri, Raquel Hontecillas
-
Patent number: 8445000Abstract: The present invention relates to immunogenic compositions, comprising polypeptides isolated from Staphylococcus epidermidis. The invention also relates to polynucleotides encoding Staphylococcus epidermidis polypeptides and their use in immunogenic compostions. In addition, the invention relates to methods of inducing an immune response in mammals against Staphylococcus epidermidis and Staphylococcus aureus using immunogenic compostions of the Staphylococcus epidermidis polypeptides and polynucleotides. The invention also relates to methods for detecting Staphylococcus epidermidis in a biological sample.Type: GrantFiled: October 19, 2005Date of Patent: May 21, 2013Assignee: Wyeth LLCInventors: Bret Richard Sellman, Steven Morris Baker
-
Patent number: 8431134Abstract: Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present of the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.Type: GrantFiled: July 31, 2009Date of Patent: April 30, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Edwin W. Ades, Gowrisankar Rajam, Sandra Steiner, George M. Carlone, Nikkoj Melnick, Jacquelyn S. Sampson, Joseph E. Martinez, Julie M. Skinner
-
Patent number: 8398996Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.Type: GrantFiled: July 17, 2009Date of Patent: March 19, 2013Assignee: Novartis AGInventors: Vega Masignani, Marirosa Mora, Maria Scarselli
-
Publication number: 20130064851Abstract: The vaccine that is protective against pathogenic bacterial species, typically staphylococcal species, and including methods to prepare said vaccine and to culture pathogenic bacteria.Type: ApplicationFiled: November 12, 2012Publication date: March 14, 2013Applicant: VACCINE RESEARCH INTERNATIONAL PLCInventor: Vaccine Research International PLC
-
Publication number: 20130064845Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.Type: ApplicationFiled: March 17, 2011Publication date: March 14, 2013Inventors: Francois Malouin, Marianne Allard, Christian Lebeau Jacob, Brian Geoffrey Talbot, Daniel Scholl, Pierre Lacasse, Moussa S. Diarra, Celine Ster
-
Patent number: 8389682Abstract: The invention relates to Staphylococcus epidermidis peptides, antibodies and nucleic acids that can inhibit Staphylococcus epidermidis infection of a mammalian subject and colonization of a medical device in the mammal.Type: GrantFiled: January 16, 2008Date of Patent: March 5, 2013Assignee: Trustees of Columbia University in the City of New YorkInventors: Carlos Arrecubieta, Mei-Ho Lee, Franklin D. Lowy
-
Patent number: 8372410Abstract: Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of S. epidermidis infections, are disclosed.Type: GrantFiled: July 3, 2012Date of Patent: February 12, 2013Assignee: Intercell AGInventors: Andreas Meinke, Min Bui Duc, Eszter Nagy
-
Patent number: 8333977Abstract: A vaccine is disclosed that is protective against pathogenic bacterial species, typically staphylococcal species, and includes methods to prepare said vaccine and to culture pathogenic bacteria.Type: GrantFiled: July 23, 2007Date of Patent: December 18, 2012Assignee: Vaccine Research International PLCInventors: Afshan Ahmad, Bruce Robert Gordon Skinner
-
Publication number: 20120308618Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.Type: ApplicationFiled: February 21, 2011Publication date: December 6, 2012Applicant: Intercell AGInventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
-
Patent number: 8323660Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:—providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—screening said at least one expression library with said antibody preparation,—identifying antigens which bind in said screening to antibodies in said antibody preparation,—screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogenType: GrantFiled: August 9, 2010Date of Patent: December 4, 2012Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitre Tempelmaier, Claire M. Fraser, Steven Gill
-
Publication number: 20120301481Abstract: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-?-glutamic acid (such as ?DLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagonosed with the infection by the Staphylococcus organism which expresses ?PGA from the cap genes. Further, the expression of a ?PGA polypeptide by the organism can then be altered.Type: ApplicationFiled: July 20, 2012Publication date: November 29, 2012Inventors: Michael Otto, Stanislava Kocianova, Cuong Vuong, Jovanka Voyich, Yufeng Yao, Elizabeth Fischer, Frank De Leo
-
Publication number: 20120282247Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve an Ebh antigen.Type: ApplicationFiled: May 7, 2012Publication date: November 8, 2012Inventors: Olaf Schneewind, Alice G. Cheng, Dominique M. Missiakas, Hwan Keun Kim
-
Publication number: 20120282295Abstract: The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.Type: ApplicationFiled: November 1, 2010Publication date: November 8, 2012Applicant: Novartis AGInventors: Paolo Costantino, Maria Rosaria Romano, Francesco Berti
-
Patent number: 8287884Abstract: The invention provides proteins from Staphylococcus aureus, including amino acid sequences and corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies, and as targets for antibiotics.Type: GrantFiled: October 6, 2009Date of Patent: October 16, 2012Assignee: Novartis AGInventors: Vega Masignani, Marirosa Mora, Maria Scarselli
-
Publication number: 20120258135Abstract: The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.Type: ApplicationFiled: January 26, 2012Publication date: October 11, 2012Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
-
Publication number: 20120244182Abstract: The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.Type: ApplicationFiled: June 4, 2012Publication date: September 27, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventor: Nicholas M. VALIANTE
-
Publication number: 20120244189Abstract: The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy.Type: ApplicationFiled: July 16, 2010Publication date: September 27, 2012Applicants: THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF, GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Timothy Foster, Judy Higgins, Elisabet Josefsson, Joan Geoghegan, Guy Dequesne, Andrej Tarkowski, Carlake Andersson
-
Publication number: 20120237549Abstract: The invention provides a process for preparing a conjugate of a S. aurens type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.Type: ApplicationFiled: September 30, 2010Publication date: September 20, 2012Applicant: Novartis AGInventors: Francesco Berti, Paolo Costantino, Maria Romano
-
Patent number: 8236325Abstract: Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of S. epidermidis infections, are disclosed.Type: GrantFiled: November 24, 2009Date of Patent: August 7, 2012Assignee: Intercell AGInventors: Andreas Meinke, Duc Min Bui, Eszter Nagy
-
Patent number: 8226958Abstract: A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.Type: GrantFiled: March 25, 2004Date of Patent: July 24, 2012Assignees: Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Kowa Company, Ltd.Inventors: Toshihiro Nakashima, Takumi Sasaki, Kazuhiko Kimachi, Shigeki Kuwata, Tsukasa Nishihara, Atsuko Sakata, Masao Ohkuchi, Tomoyuki Koshi, Toshiyuki Edano
-
Patent number: 8211445Abstract: This disclosure concerns compositions and methods for the treatment and inhibition of infectious disease, particularly methicillin-resistant Staphylococcus. In certain embodiments, the disclosure concerns immunogenic peptides, for instance PSM peptides, which can be used to induce protective immunity against methicillin-resistant Staphylococcus. Also disclosed are methods of detecting methicillin-resistant staphylococcus in a sample, and methods of diagnosing methicillin-resistant staphylococcus in a subject.Type: GrantFiled: December 4, 2009Date of Patent: July 3, 2012Assignee: The United States of America, as represented by the Department of Health and Human ServicesInventors: Michael Otto, Rong Wang
-
Publication number: 20120164076Abstract: Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to cancer. In preferred synergistic aspects, the inventive compositions (Thyex-1-6A and -6B) are administered in combination with a macrophage stimulating agent (e.g., beta glucan) for cancer treatment. Certain aspects relate to treating cancer, comprising: administering of a therapeutically effective amount of a thymus extract composition (Thyex-1-6A and -6B) in combination with administration of an extract of Houttuynia cordata. Further aspects comprise administration to a mammalian subject in need thereof a therapeutically effective amount of an extract of Houttuynia cordata, wherein treating or alleviating nausea is afforded. Combination or adjunctive therapies (e.Type: ApplicationFiled: July 2, 2010Publication date: June 28, 2012Applicant: CMI RESEARCH MANAGEMENT, LLCInventor: Richard N. Ushijima
-
Patent number: 8187585Abstract: The present invention relates to a composition comprising at least one fibronectin binding protein, and/or at least one a truncated fibronectin binding protein and/or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one iscom matrix complex and/or liposome and/or at least one lipid and at least one saponin, whereby the at least one lipid and the at least one saponin may be in complex, solution or suspension. Further, it regards use thereof for the preparation of a vaccine against a micro organism that comprises at least one fibronectin binding domain. It also relates to a kit of parts comprising at least two compartments, wherein one compartment comprises at least one truncated fibronectin binding protein and/or a fibronectin binding peptide, that comprises at least one fibronectin binding domain, and another compartment comprises an instruction for use and/or an iscom matrix complex and/or an iscom complex and or a liposome.Type: GrantFiled: July 20, 2011Date of Patent: May 29, 2012Assignee: Isconova ABInventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekstrom, Katarina Ranlund, Birgitta Fromgren, Carlos Concha Bascunan
-
Publication number: 20120114686Abstract: Disclosed are methods and compositions for treating or preventing a Staphylococcus bacterial infection using a non-toxigenic Protein A (SpA) variant.Type: ApplicationFiled: April 5, 2010Publication date: May 10, 2012Applicant: UNIVERSITY OF CHICAGOInventors: Olaf Schneewind, Alice Cheng, Dominique M. Missiakas, Hwan Keun Kim
-
Patent number: 8173774Abstract: The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of Staphylococcus aureus (‘CHIPS’), the polypeptide comprising a variant of the amino acid sequence of SEQ ID NO:1. Preferably, the polypeptide is a CHIPS variant wherein one or more of the following amino acids is modified: N31, S32, G33, L34, P35, K40, D42, R46, Y48, K50, G52, T53, K54, N55, S56, A57, Q58, K61, E67, K69, L76, N77, P79, D83, L90, K92, K100, K101, S104, K105, S107, Y108, N111 and G112. In a preferred embodiment, the polypeptide is less immunogenic hi humans than the wildtype CHIPS protein. The invention further provides methods of making and using such variant CHIPS polypeptides.Type: GrantFiled: April 20, 2007Date of Patent: May 8, 2012Assignee: Alligator Bioscience ABInventors: Christina Furebring, Johannes A. G. Van Strijp, Petrus J. A. Haas, Anna Rosen, Karin Haraldsson, Erika Gustafsson, Lena Schultz, Cornelis P. M. Van Kessel
-
Publication number: 20120107340Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.Type: ApplicationFiled: April 14, 2010Publication date: May 3, 2012Applicant: NOVARTIS AGInventors: Fabio Bagnoli, Massimilliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
-
Publication number: 20120107327Abstract: The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using immunogenic compositions of the Staphylococcus aureus polypeptides and capsule polysaccharides.Type: ApplicationFiled: June 22, 2010Publication date: May 3, 2012Applicant: WYETH LLCInventors: Annaliesa Anderson, Viliam Pavliak, Kathrin Ute Jansen, Ingrid Lea Scully, Steven Morris Baker, Jasdeep Singh Nanra, Ellen Murphy, Bruce Arthur Green, Mark Edward Ruppen, Yekaterina Timofeyeva
-
Patent number: 8168204Abstract: The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG. 1, vaccines comprising the antigenic polypeptides and therapeutic antibodies directed to the antigenic polypeptides.Type: GrantFiled: April 23, 2010Date of Patent: May 1, 2012Assignee: Absynth Biologics Ltd.Inventor: Simon J. Foster